Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) announced that its experimental drug zasocitinib demonstrated statistical superiority over deucravacitinib in a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA